Literature DB >> 17144779

Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.

Neal M Davies1, Jonathon K Reynolds, Megan R Undeberg, Brian J Gates, Yusuke Ohgami, Karina R Vega-Villa.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in treating inflammation, pain and fever, but their cardiovascular, renal and gastrointestinal toxicity can result in significant morbidity and mortality to patients. Techniques for minimizing the adverse risks of NSAIDs include avoiding use of NSAIDs where possible, particularly in high-risk patients; keeping NSAID dosages low; prescribing modified-release and enteric-coated NSAIDs; prescribing cyclooxygenase-2-selective inhibitors where appropriate; monitoring for early signs of side effects; prescribing treatments designed to minimize NSAID side effects; and developing new therapeutic strategies beyond the inhibition of cyclooxygenase. All of the above strategies can be useful in reducing the risk of NSAID complications. The optimal use and management of NSAIDs involves an individualized paradigm approach to establish efficacy with optimal tolerability given the patient risk factors for adverse events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17144779     DOI: 10.1586/14737175.6.11.1643

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

1.  Discovery of GlyT2 Inhibitors Using Structure-Based Pharmacophore Screening and Selectivity Studies by FEP+ Calculations.

Authors:  Filip Fratev; Manuel Miranda-Arango; Ashley Bryan Lopez; Elvia Padilla; Suman Sirimulla
Journal:  ACS Med Chem Lett       Date:  2019-05-22       Impact factor: 4.345

Review 2.  Novel strategies for the treatment of inflammatory hyperalgesia.

Authors:  Atul R Chopade; Wahid A Mulla
Journal:  Eur J Clin Pharmacol       Date:  2010-02-13       Impact factor: 2.953

Review 3.  Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.

Authors:  Jody K Takemoto; Jonathan K Reynolds; Connie M Remsberg; Karina R Vega-Villa; Neal M Davies
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Bromamine T, a stable active bromine compound, prevents the LPS‑induced inflammatory response.

Authors:  Stella Baliou; Michael Sofopoulos; Maria Goulielmaki; Demetrios A Spandidos; Petros Ioannou; Anthony M Kyriakopoulos; Vassilios Zoumpourlis
Journal:  Int J Mol Med       Date:  2021-02-04       Impact factor: 4.101

Review 5.  Emerging Targets for the Treatment of Osteoarthritis: New Investigational Methods to Identify Neo-Vessels as Possible Targets for Embolization.

Authors:  Reza Talaie; Pooya Torkian; Alexander Clayton; Stephanie Wallace; Hoiwan Cheung; Majid Chalian; Jafar Golzarian
Journal:  Diagnostics (Basel)       Date:  2022-06-06

6.  The role of tramadol in current treatment strategies for musculoskeletal pain.

Authors:  Stephan A Schug
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

7.  Anti-Inflammatory and Anti-Angiogenesis Effects of Verapamil on Rat Air Pouch Inflammation Model.

Authors:  Tahereh Eteraf-Oskouei; Sevda Mikaily Mirak; Moslem Najafi
Journal:  Adv Pharm Bull       Date:  2017-12-31

8.  NSAIDs as a Drug Repurposing Strategy for Biofilm Control.

Authors:  Cláudia Leão; Anabela Borges; Manuel Simões
Journal:  Antibiotics (Basel)       Date:  2020-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.